Soriot should explain the curious case of AstraZeneca’s non-deal

Share

📰 source: theguardian_business · 💼 business

astrazeneca's shares plunged 9% on monday after the ft reported preliminary takeover talks with bristol myers squibb, then recovered after reuters said discussions were off. neither company has commented, leaving shareholders in the dark about whether this was a serious move or a 'what if?'.

ceo pascal soriot has run az for 14 years without big debt-fuelled deals, concentrating on its own labs and confidently targeting $80bn revenue by 2030. a deal for bms would have been a shift, especially since bms faces patent losses on a key cancer drug and its market cap is $133bn — far larger than the $39bn alexion acquisition. possible rationales include oncology dominance, cost savings, or getting us revenues from 43% to half.

soriot should be clear whether mega-deals are now on the table, and if so, how they fit his long-term story. with ai changing pharma and his tenure winding down, investors deserve a straight answer.


why it matters: az shareholders need clarity on whether soriot's no-mega-deal strategy is quietly shifting toward risky large-scale m&a.


source: theguardian_business
sentiment: -0.10 · impact: 0.60

Read more